This is an amended filing · View original →
YUNGJIN PHARM. CO., LTD Antibiotic supply contract with Japan's MYLAN SEIYAKU extended by one year to October 2027
YAI summary · Not investment advice
YUNGJIN PHARM. CO., LTD's 2020 cephalosporin antibiotic supply contract with MYLAN SEIYAKU LTD was automatically extended from October 9, 2026 to October 9, 2027.
Contract period
Oct 10, 2020 – Oct 9, 2027
End date changed from 2026.10.09
Key facts
- Contract details
- Supply of finished cephalosporin antibiotic drugsProduct supply
- Contract amount
- KRW 12.2 billion5.5% of recent revenue · estimate based on 3 years of expected sales volume
- Recent revenue
- KRW 220.5 billion2019
- % of revenue
- 5.5%
- Counterparty
- MYLAN SEIYAKU LTD
- Contract date
- Oct 10, 2020
- Supply region
- Japan
- Payment terms
- Wire transfer · exclusive manufacture and supply of cephalosporin injections (ceftazidime and ceftriaxone sodium) that Mylan sells in Japan · auto-renews for one year unless either side objects 12 months before the end dateNo down payment or advance
Commentary
AI commentary · Not investment advice
What happened
Yungjin Pharm's 2020 antibiotic supply contract with MYLAN SEIYAKU in Japan will continue for another year. The end date moved from 2026.10.09 to 2027.10.09. The contract renews for one year automatically unless either side objects 12 months before it ends. Yungjin exclusively manufactures and supplies cephalosporin injections that Mylan sells in Japan.
In the company's terms
The contract is worth KRW 12.2 billion, or 5.5% of recent revenue (KRW 220.5 billion). That revenue figure is from 2019. The contract amount is an estimate based on three years of expected sales volume. It was converted from yen at KRW 1,080 per 100 yen.
Show Korean comments
Comments
No comments yet
Comments from shareholders will appear here.
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist